Cart
sales@molnova.com
B-Raf IN 16
CAS No. 2304746-24-3
B-Raf IN 16( —— )
Catalog No. M37248 CAS No. 2304746-24-3
B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 296 | Get Quote |
|
| 5MG | 459 | Get Quote |
|
| 10MG | 657 | Get Quote |
|
| 25MG | 994 | Get Quote |
|
| 50MG | 1371 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameB-Raf IN 16
-
NoteResearch use only, not for human use.
-
Brief DescriptionB-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.
-
DescriptionB-Raf IN 16 (Compound I) is a BRAF inhibitors that belongs a cyclic iminopyrimidine derivative. B-Raf IN 16 can be used for cancer research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorRaf
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2304746-24-3
-
Formula Weight409.46
-
Molecular FormulaC20H19N5O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CC=1C(OC=2C=CC=3N=CN4C(=NCC4)C3C2)=CC=CC1NS(=O)(=O)CCC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chen Chen. Cyclic iminopyrimidine derivatives as kinase inhibitors
molnova catalog
related products
-
BI 882370
BI 882370 is a highly potent, selective, orally active RAF inhibitor with IC50 of 0.4, 0.8 and 0.6 nM for BRAF V600E, BRAF WT and CRAF, respectively.
-
R18
Antagonist of 14.3.3 proteins (KD ≈80 nM). Competitively inhibits 14.3.3-ligand interactions without requiring phosphorylation. Blocks the ability of 14.3.3 to bind to target proteins such as Raf-1, Bad, ASK1 and exoenzyme S.
-
LUT014
LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.
